Search

Your search keyword '"O. Grimm"' showing total 400 results

Search Constraints

Start Over You searched for: Author "O. Grimm" Remove constraint Author: "O. Grimm"
400 results on '"O. Grimm"'

Search Results

1. Integrating digital pathology and mathematical modelling to predict spatial biomarker dynamics in cancer immunotherapy

2. FCC Physics Opportunities

4. IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany

9. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

11. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

13. 1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

14. 1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany

17. Neprilysin and Aβ-clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer´s disease

20. Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial

21. IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany

22. Influence of prostate artery embolization on different qualities of micturition disorders

23. Förderung und Unterstützung der erfolgreichen Ausbildung zum Urologen durch die Deutsche Gesellschaft für Urologie

24. Erstlinientherapie des mRCC: ein Update

25. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination

26. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

31. Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

33. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

34. Alpharadin-Therapie bei Patienten mit metastasiertem kastrationsrefraktärem Prostatakarzinom

35. Metastasiertes Prostatakarzinom

36. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

37. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

38. [Risk-adapted therapy for metastatic renal cell carcinoma]

39. HE-LHC: The High-Energy Large Hadron Collider Future Circular Collider Conceptual Design Report Volume 4

40. Risikoadaptierte Therapie des metastasierten Nierenzellkarzinoms

41. Aktueller Stand der Immunonkologie bei urologischen Tumoren

42. Metastasiertes kastrationsresistentes Prostatakarzinom

43. Diagnostik und Therapie retroperitonealer Abszesse

44. Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition

45. Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA

46. Erratum to : An update on renal cell carcinoma

47. [Promotion and support of successful training as a urologist by the Deutsche Gesellschaft für Urologie]

48. [Follow-up of renal cell carcinoma in a nonmetastatic stage]

49. T2 Mapping in Prostate Cancer

50. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]

Catalog

Books, media, physical & digital resources